Alvaro Alencar, MD

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Alvaro Alencar, MD sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting early-phase tilt upper half by trial count

Alvaro Alencar, MD: 1 sponsored US clinical trial, 1 recruiting.

Alvaro Alencar, MD sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Mantle Cell Lymphoma, with 1 trials.

Mid-pack sponsor footprint

Alvaro Alencar, MD is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Phase Distribution

PhaseTrial count
Phase 1 1

Therapeutic Areas

What is open in the Alvaro Alencar, MD pipeline

1 recruiting of 1 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Mantle Cell Lymphoma (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Alvaro Alencar, MD: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Alvaro Alencar, MD sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Alvaro Alencar, MD1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Alvaro Alencar, MD sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Alvaro Alencar, MD sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

What to do with this Alvaro Alencar, MD page

1 registered trials is a research-attention snapshot, not an endorsement of Alvaro Alencar, MD or any single study.

  • 1 of Alvaro Alencar, MD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Mantle Cell Lymphoma is the condition Alvaro Alencar, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Mantle Cell Lymphoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Alvaro Alencar, MD pipeline card: 1 registered trials from official public datasets.Report a data error.